CD274 and neoplasm: Intriguingly, anti-PD-L1 treated recipients diverged into three groups: responders (R), slow progressors (SP) and non-responders (NR) (Figure 1B), defined based on relative change in tumor volume (RCTV) at the end of experiments (Figure 1C) (see details in Method).